Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03058575 · ClinicalTrials.gov registry record · NA
Effects of a Novel Food Product Containing Microbiota Accessible Carbohydrates on the Human Microbiome
A NA study, sponsored by Access Business Group.
- Completed
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT03058575: Completed NA study, sponsored by Access Business Group.
NCT03058575 is a NA study that has completed, run by Access Business Group. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03058575, a NA study, has completed, sponsored by Access Business Group.
- COMPLETED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a randomized, 2-period crossover study aimed at assessing the effect of taking a food supplement containing a blend of microbial accessible carbohydrates on the diversity of the gut microbiome. Impacts to the skin, scalp and oral microbiomes; blood inflammatory biomarkers; quality and quantity of sleep; gastrointestinal quality of life; bowel habits, and facial skin features will also be evaluated.
Primary Outcome
The Shannon Diversity Index of the fecal microbiome will be measured at each of the time points via taxonomic profiling using 16S ribosomal RNA gene amplicon sequencing
Interventions
- OTHER Control
- DIETARY_SUPPLEMENT Dietary MACs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-01-16 |
| Est. Completion | 2017-09-30 |
| Phase | NA |
What the finished NCT03058575 record still lists
NCT03058575 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which Control is the first listed.
NCT03058575 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03058575 about?
NCT03058575 is a clinical study titled "Effects of a Novel Food Product Containing Microbiota Accessible Carbohydrates on the Human Microbiome". This is a randomized, 2-period crossover study aimed at assessing the effect of taking a food supplement containing a blend of microbial accessible carbohydrates on the diversity of the gut microbiome. Impacts to the skin, scalp and oral microbiomes; blood inflammatory biomarkers; quality and quanti...
What is the current status of trial NCT03058575?
This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2017-01-16. Estimated completion is 2017-09-30.
What interventions are being tested in trial NCT03058575?
The interventions under investigation include: Control (OTHER), Dietary MACs (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT03058575?
This trial is sponsored by Access Business Group, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03058575's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI